Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomp...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Levis, Mark, Ravandi, Farhad, Wang, Eunice S., Baer, Maria R., Perl, Alexander, Coutre, Steven, Erba, Harry, Stuart, Robert K., Baccarani, Michele, Cripe, Larry D., Tallman, Martin S., Meloni, Giovanna, Godley, Lucy A., Langston, Amelia A., Amadori, Sergio, Lewis, Ian D., Nagler, Arnon, Stone, Richard, Yee, Karen, Advani, Anjali, Douer, Dan, Wiktor-Jedrzejczak, W., Juliusson, Gunnar, Litzow, Mark R., Petersdorf, Stephen, Sanz, Miguel, Kantarjian, Hagop M., Sato, Takashi, Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald, Smith, B. Douglas
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2011
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3069671/
https://ncbi.nlm.nih.gov/pubmed/21270442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-301796
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi